SMMT Q2 2024 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$20,000

Operating Income

-$60M

Net Income

-$60M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$342M

Total Liabilities

$147M

Stockholders' Equity

$195M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$235,000	-100.0%
Gross Profit	-$20,000	-$236,000	+91.5%
Operating Income	-$60M	-$16M	-277.5%
Net Income	-$60M	-$15M	-310.3%